Your SlideShare is downloading. ×
Pink army july 31
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Pink army july 31

291
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
291
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. @ANDREW HESSEL JULY 31 02010 a drug company for everyone PINK ARMY COOPERATIVE
  • 2. http://ilovebacteria.com/Images/bacterialcell.jpg http://i.dell.com/images/global/products/314x314/desktop-studio-mini-left-314.jpg
  • 3.  
  • 4.  
  • 5. andrew hessel
  • 6.  
  • 7. COMPILE DESIGN design/build/test cycle EXECUTE TEST applications
  • 8. David Appleyard
  • 9.  
  • 10.  
  • 11.  
  • 12.  
  • 13. CANCER
  • 14.  
  • 15.  
  • 16. CANCER R&D IS
  • 17.  
  • 18. Evolutionary distance ~ 4 billion years two completely different species, far removed, and bacteria are clonal
  • 19. many chemical compounds have antimicrobial activity without seriously harming human cells
  • 20.  
  • 21. Evolutionary distance max: patient’s age cancer cells are same species, only recently diverged, and every divergence is unique, cells continue to degrade over time (mixed)
  • 22.  
  • 23. photo by billy hunt
  • 24.  
  • 25. christa slotboom
  • 26. TARGETING FAST GROWING CELLS IS SO 1950 there are plenty of normal cells that grow fast too, making treatments needlessly harsh ONE-SIZE-FITS-ALL DRUGMAKING IS ILLOGICAL each person’s DNA is different, their mutations are different, cancers are of mixed cell types CANCER RESEARCHERS DON’T MAKE DRUGS drug companies make drugs A LOT OF RESEARCH ISN’T USEFUL there appears to be a near-infinite number of paths to cancer CHANGE IS HARD cancer is industry with tremendous inertia
  • 27. THE IDEAL THERAPEUTIC specific to the cancer gentle effective made quickly inexpensive
  • 28. http://www.nature.com/horizon/chemicalspace/background/images/odyssey-f1.jpg
  • 29. Scientists new drug X shareholders Lawyers MANUFACTURERS clinical trials Economists physicians Insurance companies geneticists
  • 30.  
  • 31. system is inherently limited requires blockbusters unable to accelerate
  • 32. RISK vs BENEFIT ( n >1) STATISTICAL ANALYSIS OF POPULATIONS requires large markets failure is expensive political slow
  • 33. RISK vs BENEFIT ( n =1) no statistics – just direct observations risk benefit analysis always an individual decision ?
  • 34. isolate and analyze design build test failures provide and evaluate SYNTHETIC BIOLOGY BIOFAB results COOPERATIVE data sharing
  • 35.  
  • 36.  
  • 37. aims to bring together researchers, developers, cancer sufferers and supporters in a self-funded, open-source therapeutic venture
  • 38. goal: not a new drug, but a completely new way of making drugs one that can accelerate and improve over time
  • 39. a significant step towards faster, better, cheaper cancer drugs + =
  • 40. diagnostics today, treatments tomorrow
  • 41. pinkarmy.org join us